Patents by Inventor Klaus Dugi

Klaus Dugi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF A DPP-4 INHIBITOR IN SIRS AND/OR SEPSIS
    Publication number: 20220340575
    Abstract: The present invention relates to methods for treating and/or preventing SIRS and/or sepsis comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and/or preventing a metabolic disease in a patient with or at risk of SIRS and/or sepsis.
    Type: Application
    Filed: April 27, 2022
    Publication date: October 27, 2022
    Inventors: Thomas KLEIN, Andreas DAIBER, Klaus DUGI, Michael MARK, Thomas MUENZEL
  • TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY
    Publication number: 20220323434
    Abstract: The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients for whom metformin therapy is inappropriate due to intolerability or contraindication against metformin.
    Type: Application
    Filed: June 13, 2022
    Publication date: October 13, 2022
    Inventors: Klaus DUGI, Eva Ulrike GRAEFE-MODY, Ruth HARPER, Hans-Juergen WOERLE
  • USES OF DPP IV INHIBITORS
    Publication number: 20220184088
    Abstract: The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.
    Type: Application
    Filed: February 28, 2022
    Publication date: June 16, 2022
    Inventors: Klaus DUGI, Frank HIMMELSBACH, Michael MARK
  • Uses of DPP IV inhibitors
    Patent number: 11291668
    Abstract: The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.
    Type: Grant
    Filed: March 25, 2020
    Date of Patent: April 5, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Klaus Dugi, Frank Himmelsbach, Michael Mark
  • TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY
    Publication number: 20210093633
    Abstract: The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients for whom metformin therapy is inappropriate due to intolerability or contraindication against metformin.
    Type: Application
    Filed: December 11, 2020
    Publication date: April 1, 2021
    Inventors: Klaus DUGI, Eva Ulrike GRAEFE-MODY, Ruth HARPER, Hans-Juergen WOERLE
  • USES OF DPP IV INHIBITORS
    Publication number: 20200222411
    Abstract: The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.
    Type: Application
    Filed: March 25, 2020
    Publication date: July 16, 2020
    Inventors: Klaus DUGI, Frank HIMMELSBACH, Michael MARK
  • Uses of DPP IV inhibitors
    Patent number: 10668074
    Abstract: The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: June 2, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Klaus Dugi, Frank Himmelsbach, Michael Mark
  • TREATMENT OF GENOTYPED DIABETIC PATIENTS WITH DPP-IV INHIBITORS SUCH AS LINAGLIPTIN
    Publication number: 20200046713
    Abstract: The present invention relates to methods for preventing or treating of metabolic disorders and related conditions, such as in certain patient groups.
    Type: Application
    Filed: August 1, 2019
    Publication date: February 13, 2020
    Inventors: Klaus DUGI, Eva Ulrike GRAEFE-MODY, Michael MARK, Hans-Juergen WOERLE, Heike ZIMDAHL-GELLING
  • USE OF A DPP-4 INHIBITOR IN SIRS AND/OR SEPSIS
    Publication number: 20190202833
    Abstract: The present invention relates to methods for treating and/or preventing SIRS and/or sepsis comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and/or preventing a metabolic disease in a patient with or at risk of SIRS and/or sepsis.
    Type: Application
    Filed: March 8, 2019
    Publication date: July 4, 2019
    Inventors: Thomas KLEIN, Andreas DAIBER, Klaus DUGI, Michael MARK, Thomas MUENZEL
  • TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY
    Publication number: 20190105321
    Abstract: The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients for whom metformin therapy is inappropriate due to intolerability or contraindication against metformin.
    Type: Application
    Filed: December 5, 2018
    Publication date: April 11, 2019
    Inventors: Klaus DUGI, Eva Ulrike GRAEFE-MODY, Ruth HARPER, Hans-Juergen WOERLE
  • TREATMENT OF GENOTYPED DIABETIC PATIENTS WITH DPP-IV INHIBITORS SUCH AS LINAGLIPTIN
    Publication number: 20190000855
    Abstract: The present invention relates to methods for preventing or treating of metabolic disorders and related conditions, such as in certain patient groups.
    Type: Application
    Filed: September 5, 2018
    Publication date: January 3, 2019
    Inventors: Klaus DUGI, Eva Ulrike GRAEFE-MODY, Michael MARK, Hans-Juergen WOERLE, Heike ZIMDAHL-GELLING
  • USES OF DPP IV INHIBITORS
    Publication number: 20180353513
    Abstract: The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.
    Type: Application
    Filed: August 14, 2018
    Publication date: December 13, 2018
    Inventors: Klaus DUGI, Frank HIMMELSBACH, Michael MARK
  • Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
    Patent number: 10092571
    Abstract: The present invention relates to methods for preventing or treating of metabolic disorders and related conditions, such as in certain patient groups.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: October 9, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Klaus Dugi, Eva Ulrike Graefe-Mody, Michael Mark, Hans-Juergen Woerle, Heike Zimdahl-Gelling
  • TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY
    Publication number: 20180271859
    Abstract: The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients for whom metformin therapy is inappropriate due to intolerability or contraindication against metformin.
    Type: Application
    Filed: May 29, 2018
    Publication date: September 27, 2018
    Inventors: Klaus DUGI, Eva Ulrike GRAEFE-MODY, Ruth HARPER, Hans-Juergen WOERLE
  • Uses of DPP IV inhibitors
    Patent number: 10080754
    Abstract: The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: September 25, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Klaus Dugi, Frank Himmelsbach, Michael Mark
  • Treatment for diabetes in patients inappropriate for metformin therapy
    Patent number: 10034877
    Abstract: The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients for whom metformin therapy is inappropriate due to intolerability or contraindication against metformin.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: July 31, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Klaus Dugi, Eva Ulrike Graefe-Mody, Ruth Harper, Hans-Juergen Woerle
  • USES OF DPP IV INHIBITORS
    Publication number: 20170087160
    Abstract: The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.
    Type: Application
    Filed: December 8, 2016
    Publication date: March 30, 2017
    Inventors: Klaus DUGI, Frank HIMMELSBACH, Michael MARK
  • TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY
    Publication number: 20170020868
    Abstract: The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients for whom metformin therapy is inappropriate due to intolerability or contraindication against metformin.
    Type: Application
    Filed: October 6, 2016
    Publication date: January 26, 2017
    Inventors: Klaus DUGI, Eva Ulrike GRAEFE-MODY, Ruth HARPER, Hans-Juergen WOERLE
  • TREATMENT OF GENOTYPED DIABETIC PATIENTS WITH DPP-IV INHIBITORS SUCH AS LINAGLIPTIN
    Publication number: 20160354380
    Abstract: The present invention relates to methods for preventing or treating of metabolic disorders and related conditions, such as in certain patient groups.
    Type: Application
    Filed: August 12, 2016
    Publication date: December 8, 2016
    Inventors: Klaus DUGI, Eva Ulrike GRAEFE-MODY, Michael MARK, Hans-Juergen WOERLE, Heike ZIMDAHL-GELLING
  • Treatment for diabetes in patients inappropriate for metformin therapy
    Patent number: 9486526
    Abstract: The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients for whom metformin therapy is inappropriate due to intolerability or contraindication against metformin.
    Type: Grant
    Filed: June 3, 2014
    Date of Patent: November 8, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Klaus Dugi, Eva Ulrike Graefe-Mody, Ruth Harper, Hans-Juergen Woerle